Weekly Recap | ARKG.US +13.35%, AI healthcare leads genomics themeWeekly Review·Sep 19 at 07:15 AMARKG+2.05%
Weekly Recap | Twist Bioscience +31.26%, signs deal with Lilly TuneLabWeekly Review·Sep 19 at 06:54 AMTWST-0.74%
Weekly Recap | Adma Biologics -4.05%, rally fades into pullbackWeekly Review·Sep 12 at 07:41 AMADMA+3.21%
The Nasdaq Biotechnology Index rose over 2.6%, outperforming the broader US stock market. Among constituents, Sarepta Therapeutics surged 34.98%, Summit Therapeutics Plc. rose 15.53%, Enliven Therapeutics increased 14.06%, Upstream Bio gained 12.07%, Taysha Gene climbed 10.90%, Gossamer Bio advanced 10.61%, and Oruka Therapeutics was up 9.80%. Conversely, Aardvark Therapeutics fell 6.10%, ADMA Biologics dropped 15.23%, Anavex Life Sciences declined 34.61%, and Maze Therapeutics fell 35.24%Wallstreetcn·Mar 25 at 08:50 PMXBI+2.30%TSHA+2.38%
The Nasdaq Biotechnology Index rose by 1.29%. Among the constituent stocks, CG Oncology increased by 24.99%, UroGen Pharma rose by 14.08%, and ADMA Biologics climbed by 12.03%. In contrast, Neurogene fell by 5.91%, Amylyx Pharmaceuticals dropped by 6.53%, and Q32 Bio decreased by 9.89%Wallstreetcn·Apr 28, 2025 at 08:42 PMCGON-0.65%ADMA+3.21%
